UK biotech firm to re-domicile to Bermuda
A UK- based biotechnology company is to re-domicile to Bermuda.
Tiziana Life Sciences plc confirmed that it has re-activated its strategic plan to re-domicile to the island following the company’s annual general meeting held earlier yesterday.
The company said shareholders will receive further information in due course.
Tiziana said it is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology.
In addition to Milciclib, a CDK inhibitor being developed in oncology, the company said it is also developing Foralumab in Covid-19, multiple sclerosis, and Crohn’s disease.
It added that Foralumab is the only second generation fully human anti-CD3 monoclonal antibody in clinical development in the world.
Tiziana said this Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), Crohn's disease, psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable.
The company said it is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammatory pulmonary diseases.
Need to
Know
2. Please respect the use of this community forum and its users.
3. Any poster that insults, threatens or verbally abuses another member, uses defamatory language, or deliberately disrupts discussions will be banned.
4. Users who violate the Terms of Service or any commenting rules will be banned.
5. Please stay on topic. "Trolling" to incite emotional responses and disrupt conversations will be deleted.
6. To understand further what is and isn't allowed and the actions we may take, please read our Terms of Service
